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Background: Recent increases in cardiovascular risk-factor prevalences have led to new national policy
recommendations of universal screening for primary prevention of cardiovascular disease in Malaysia. This study
assessed whether the current national policy recommendation of universal screening was optimal, by comparing
the effectiveness and impact of various cardiovascular screening strategies.
Methods: Data from a national population based survey of 24 270 participants aged 30 to 74 was used. Five
screening strategies were modelled for the overall population and by gender; universal and targeted screening
(four age cut-off points). Screening strategies were assessed based on the ability to detect high cardiovascular risk
populations (effectiveness), incremental effectiveness, impact on cardiovascular event prevention and cost of
screening.
Results: 26.7% (95% confidence limits 25.7, 27.7) were at high cardiovascular risk, men 34.7% (33.6, 35.8) and
women 18.9% (17.8, 20). Universal screening identified all those at high-risk and resulted in one high-risk individual
detected for every 3.7 people screened, with an estimated cost of USD60. However, universal screening resulted in
screening an additional 7169 persons, with an incremental cost of USD115,033 for detection of one additional high-
risk individual in comparison to targeted screening of those aged ≥35 years. The cost, incremental cost and impact
of detection of high-risk individuals were more for women than men for all screening strategies. The impact of
screening women aged ≥45 years was similar to universal screening in men.
Conclusions: Targeted gender- and age-specific screening strategies would ensure more optimal utilisation of
scarce resources compared to the current policy recommendations of universal screening.
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Malaysia is one of the many developing countries in the
world that has undergone epidemiologic and demo-
graphic transition. Recent national health reports
showed a rising prevalence of several risk factors [1] and
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reproduction in any medium, provided the orHowever, information on risk factor prevalence alone is
insufficient to provide adequate knowledge on the risk
of future cardiovascular events. It is well known that a
constellation of low to moderately elevated risk factors
can confer a higher cardiovascular risk in an individual
than just one highly elevated risk factor [3,4]. For
example, a 45 year old male smoker, non diabetic with a
total cholesterol level (TC) of 5.4 mmol/l, systolic blood
pressure (SBP) of 150 mmHg and a HDL cholesterol
level of 1.2 mmol/l has an overall 10-year cardiovascular
disease risk of 17% compared to 8.9% of a 50 year oldral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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total cholesterol of 4.3 mmol/l and HDL of 1.9 mmol/l
(using the Framingham Risk Score). Therefore, cardio-
vascular risk estimation is an important component of
estimating the overall effects of risk factors.
Recently, the Ministry of Health, Malaysia developed a
national strategic plan to tackle the burgeoning increase
in cardiovascular risk factors and disease. Among the
various strategies and key activities planned are screening
strategies to identify individuals at high cardiovascular risk
to institute early clinical management. The two proposed
strategies are: 1) to start community based risk factor
screening (universal screening) and 2) to make policy and
regulation changes to include compulsory screening for all
employees aged 40 and above [5].
However, before the implementation of national pol-
icies, the most effective screening strategy should be iden-
tified. In this study, we hope to answer three questions; 1)
What is the distribution of overall cardiovascular risk in
Malaysia? 2) What are the more effective screening strat-
egies to identify high-risk populations? and 3) What are
the impact (numbers of cardiovascular events prevented)
and estimated costs for these strategies?
Methods
Study population
This study used data from the National Health and Mor-
bidity Survey (NHMS III) conducted in 2006. The NHMS
is a national population based survey held every ten years,
that assesses various aspects of health care, including bur-
den of disease, health care utilisation and costs. The
NHMS III used a two-stage stratified random sampling
strategy proportionate to the population size of Malaysia.
All data were collected via a face-to-face interview using a
bi-lingual (Malay language and English) pre-coded ques-
tionnaire. The NHMS III was funded by the Ministry of
Health Malaysia and ethics approval was obtained from
the Medical Research and Ethics Committee, Ministry
of Health Malaysia. Written informed consent was
obtained from all participants prior to the interview and
examinations. Details of this survey have been published
previously [1]. Briefly, blood pressure was measured using
the average of two readings of systolic and diastolic blood
pressure taken at rest, 15 minutes apart. Blood glucose
levels were measured after an overnight fast. Height was
measured without shoes to the nearest 0.1 centimetre and
body weight was measured in light clothing without shoes
to the nearest 0.1 kilogramme.
Survey participants aged 30 to 74 years were selected
for this study.
Overall cardiovascular risk
Overall cardiovascular risk was estimated using the
Framingham Risk Score (FRS) for general cardiovasculardisease (10-year risk) [6]. Events of this risk score are
coronary death, myocardial infarction, coronary insuffi-
ciency, angina, ischaemic stroke, haemorrhagic stroke,
transient ischaemic attack, peripheral artery disease and
heart failure. The FRS used a simple office-based non-
laboratory set of variables. We used the formula with
body mass index (BMI) as a substitute for total
and high-density lipoprotein (HDL) cholesterol levels,
because in the NHMS III, HDL cholesterol levels were
not measured. The variables were logarithm of age, loga-
rithm of BMI, logarithm of systolic blood pressure (SBP)
(with different regression coefficients for treated or
untreated high blood pressure), smoking and diabe-
tes mellitus (website: http://www.framinghamheartstudy.
org/risk/gencardio.html).
An example is given below: The 10-year risk of cardio-
vascular disease for men who were not treated for hyper-
tension was calculated as 1–0.88431exp((3.11296*logage) +
(0.79277*logBMI) + (1.85508*logUntreatedSBP) + (0.70953*smoking) +
(0.53160*diabetes) – 23.9388).
Framingham risk definitions
High risk individuals were defined as those whose
10-year risk of cardiovascular disease was more or equal
to 20%. Those at intermediate risk were between 10 to
20% and low risk was less than 10%.
Statistical analyses
A complex survey analysis weighted for non-response,
as well as population age and sex demographics, was
used to produce correct estimations for the Malaysian
population. Prevalences, screening coverage and detec-
tion rates of populations at high cardiovascular risk were
estimated.
Prevalence estimates for demographics and cardiovas-
cular risk factors were given by the Framingham risk cat-
egories, as well as overall. Variance was estimated using
the Taylor linearization method [7]. Group differences
between risk categories for continuous variables were
estimated using an adjusted Wald test (F statistic).
Differences between the risk categories for categorical
variables were tested using Pearson’s chi square test,
adjusted for design effect (F statistic).
For all analyses, p values less than 0.05 were considered
statistically significant. Analyses were performed using
Stata Statistical Software: Release 11.0 (College Station,
TX: Stata Corporation LP).
Simulated screening strategies
For the purpose of this study, only the universal (com-
munity-based) screening policy recommendation was
assessed, because this strategy will be funded by the
government, and it encompasses the entire population.
The other screening strategies chosen for simulation in
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offs. Stratification by gender was included to determine
if gender-specific screening strategies were required. The
coverage, effectiveness and impact of screening strategies
were simulated for:
1. Universal screening (aged 30 and above)
2. Those aged 35 and above
3. Those aged 40 and above
4. Those aged 45 and above
5. Those aged 50 and above
Effectiveness
Effectiveness was assessed as the ability of a screening
strategy to identify individuals of high cardiovascular
risk as classified by the FRS. Comparisons of effective-
ness were determined using the numbers needed to
screen (NNS) to detect one high-risk individual. Incre-
mental effectiveness was determined as the additional
number of individuals needed to be screened to detect
one high-risk individual. Strategies were compared with
a lower age cut-off for screening eligibility.
Impact
The impact of each screening strategy was assessed by the
NNS to prevent one cardiovascular event among individuals
at high risk. The number of cardiovascular events prevented
was determined using the following formula [8]:
Number of cardiovascular events prevented = N x Car-
diovascular disease rate x (1-((1- pd x pu x pc x RRR)int
1 x -(1- pd x pu x pc x RRR)int 2 x . . .x -((1- pd x pu x
pc x RRR)int n)
Where,
 N= number of high-risk people in respective
screening strategy
 Cardiovascular disease rate = average FRS score for
respective screening strategy
 pd = proportion of high-risk people with disease/
risk factor requiring intervention
 pu = proportion of high-risk people with disease/ risk
factor requiring intervention that take up the
intervention
 pc = proportion of adequacy of control /adherence
to intervention
 RRR = relative risk reduction achieved with
intervention [9-12]
The interventions that were assessed in the simulation
models were antihypertensive, lipid lowering and glucose
lowering drugs, and smoking cessation therapies.
Sensitivity analyses We carried out sensitivity analyses
to account for uncertainties in the parameters chosenfor measuring the impact of the respective screening
strategies. The parameters were for uptake of treatment,
adherence to treatment and the relative risk reductions
for those adhering to treatment. The uptake of treatment
was calculated as a 30% reduction from the actual
uptake seen in the NHMS III. Values for adherence to
treatment and relative risk reductions were obtained
from the lower limits of their 95% confidence intervals
[1,9-13].
Table 1 depicts the percentage of individuals with a
cardiovascular risk factor who decide to accept treat-
ment, the percentage adhering to treatment and the
relative risk reduction for those adhering to treatment,
and the respective values chosen for sensitivity analyses.
Cost
Cost estimations for each screening strategy were
calculated using the Malaysian Medical Association’s
Schedule of Fees [14]. The recommended fee for
screening is Malaysian Ringgit (MYR) 50.00 (about
USD16.00).
Assumptions Those who do not adhere to therapies
have the same 10-year risk of cardiovascular disease as
those untreated. All interventions are independent of
each other and there are no additive nor multiplicative
effects.
Results
There were 24 270 participants from the NHMS III
survey between the ages 30 to 74 years. Women made
up 55.2% of the population (13 393 participants).
Distribution of overall cardiovascular risk
26.7% (95% confidence limits 25.7, 27.7) were in the high
risk category, 20.3% (19.8, 20.9) were at intermediate risk
and 53% (51.8, 54.1) were in the low risk category
(Table 2). Among those in the low risk category, a quar-
ter had hypertension and almost 40% were centrally
obese.
Overall, 34.7% (33.6, 35.8) men and 18.9% (17.8, 20) of
women (p = 0.0001).were considered at high risk. For
every age group, there were far more men at high risk of
cardiovascular disease (Figure 1). The prevalence of high
risk was similar in urban and rural areas (Figure 2).
Coverage and detection of populations at high
cardiovascular risk
As the cut-off age for screening strategies reduced, more
of the general population were eligible for screening
(Table 3). However, despite the increase in coverage of
53.3% from the cut-off age of ≥50 to universal screening,
the coverage of high risk populations only increased by
5.6%. Aside from this, the high risk individuals detected
Table 1 Uptake and adherence to treatment, and relative risk reductions for cardiovascular interventions
Therapy/ Intervention Percentage of uptake * Percentage of adherence* RRR ‡
Antihypertensives 87.5 26.3 0.22
Lipid lowering drugs 44.1 69 0.22
Hypoglycaemic agents 85.8 29.3† 0.1
Smoking cessation 70.6 9.30 0.36
Sensitivity analyses
Antihypertensives 57.5 24.8 0.17
Lipid lowering drugs 14.1 65.3 0.18
Hypoglycaemic agents 55.8 17.1 0.02
Smoking cessation 40.6 8.9 0.29
* from the NHMS III (1).
† from the diabetes registry Malaysia (13).
‡ from meta-analysis on effects on interventions on CVD events (5–8).
RRR relative risk reduction.
Table 2 Characteristics of study participants by their overall cardiovascular risk
Overall Low risk Intermediate risk High risk p value
Variables
Age 49.4 (0.01) 48.4 (0.03) 49.7 (0.03) 52.9 (0.13)
Male sex 49.6 40 55 64.3 <0.001
Race 0.008
Malay 48.4 47.2 48.3 50.9
Chinese 29.6 28.3 30.3 31.5
Asian Indian 7.8 7.9 8.2 7.4
Others 14.2 16.6 13.2 10.1
Residence 0.007
Urban 60.8 64.3 58 55.8
Rural 39.2 35.7 42 44.2
Education (Years of schooling) <0.001
Tertiary (≥ 13 years) 7.8 11.1 5.8 2.8
Secondary (7–12 years) 41.7 54.3 33.7 22.9
Primary (≤6 years) 35.4 26.4 40.9 49
Household income <0.001
<RM2000 62.4 57.1 64.4 71.4
RM2000-3999 23.9 26.3 23.1 19.8
≥RM4000 13.7 16.6 12.5 8.8
Prevalences of CV risk factors
Smoking 22.2 (20.3, 24.3) 16.6 (14.8, 18.5) 25.9 (23.8, 28.0) 30.7 (27.7, 33.8) <0.001
Central obesity 44.6 (42.6, 46.5) 38.4 (36.7, 40.2) 48.5 (45, 51.9) 53.8 (51, 56.5) <0.001
Hypertension 50.1 (48.1, 52.2) 26.1 (24.4, 28.1) 64.3 (62.2, 66.5) 87 (85.9, 88) <0.001
Hypercholesterolemia 30.3 (27.7, 33) 23.2 (21.0, 25.5) 35.9 (32.6, 39.3) 40.1 (36.8, 43.6) <0.001
Diabetes 15.2 (13.8, 16.7) 4 (3.4, 4.6) 15.4 (13.7, 17.3) 37.3 (33.7, 41) <0.001
Data are % for categorical variables, mean (se) for continuous variables & prevalence (95%CI) for risk factors.
CV cardiovascular.
Smoking; current smokers who smoked ≥100 cigarettes in their lifetime, and smoked daily or for some days in.
The previous month.
Central obesity; men, 90 cm and women, 80 cm [25].
Hypertension; SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg [26], or use of anti-hypertensive medication.
Hypercholesterolemia; total cholesterol level ≥ 5.2 mmol/l [27] or use of lipid lowering drugs.
Diabetes; fasting glucose ≥ 6.1 mmol/l [28] or self reported to be diabetic.
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Figure 1 Percentage of males and females with high overall cardiovascular risk (> = 20% ten year risk) by age categories.
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as the screened populations got larger.
Effectiveness of screening strategies
The NNS to detect one high-risk individual increased as
the cut-off age for screening was reduced. With univer-
sal screening, one high-risk individual was detected for
every four people screened. Whereas, when only those
over age 50 years were screened, one high-risk individual
was detected for every two persons screened (Table 3).
Furthermore, the NNS for men with universal screening
(2.88) was far smaller than the NNS for women (5.30).
Incremental effectiveness of screening strategies
As the screening population was extended (younger ages
were included), the additional coverage of high-risk
populations decreased, the percentage of additional high-Figure 2 Percentage of urban and rural populations with high overalrisk individuals detected reduced and the additional num-
ber of individuals needed to be screened to detect one
high-risk individual increased tremendously (Table 4).
These findings were similar for men and women.
Impact
With universal screening, 147 people have to be screened
and treated for 10 years to prevent one cardiovascular
event (Table 5). For men, the NNS and treat for 10 years,
to prevent a single cardiovascular event was lower than
women for all screening strategies. These values increased
by up to 2.6 – 2.8 times when accounted for uncertainties
in the parameters.
Cost of screening strategies
The estimated cost of detecting each high-risk individual
increased as the screening strategy progressively encompassedl cardiovascular risk (> = 20% ten year risk) by age categories.
Table 3 Coverage and detection of high cardiovascular risk populations for various screening strategies
Targeted screening Universal
≥ age 50 ≥ age 45 ≥ age 40 ≥ age 35 screening
Overall
Coverage of population 46.72 58.06 70.13 84.47 100.00
Coverage of high risk population 94.39 98.71 99.82 100.00 100.00
% of high risk individuals - among those screened 53.97 45.42 38.02 31.62 26.71
NNS to detect 1 high risk individual (no.) 1.85 2.20 2.63 3.16 3.74
Males
Coverage of population 44.36 56.32 68.82 83.95 100.00
Coverage of high risk population 92.60 98.22 99.75 100.00 100.00
% of high risk individuals - among those screened 72.41 60.50 50.28 41.32 34.69
NNS to detect 1 high risk individual (no.) 1.38 1.65 1.99 2.42 2.88
Females
Coverage of population 49.03 59.76 71.41 84.98 100.00
Coverage of high risk population 97.61 99.58 99.99 100.00 100.00
% of high risk individuals - among those screened 37.59 31.47 26.43 22.22 18.88
NNS to detect 1 high risk individual (no.) 2.66 3.18 3.78 4.50 5.30
All data are in percentage (%) unless otherwise stated.
NNS numbers needed to screen.
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screening strategies of the universal screening and
those aged ≥50 years, the cost for detecting a single
high-risk individual slightly more than doubled. The
cost of detecting high-risk individuals among men were
almost half that of women, for all screening strategies.Table 4 Incremental coverage and detection of high cardiova
≥ age 50†
Strategies implemented incrementally*
Additional % of population screened -
Additional coverage of high risk population screened -
% of additional high risk individuals detected -
Additional NNS to detect 1 high risk individual -
Males
Additional % of population screened -
Additional coverage of high risk population screened -
% of additional high risk individuals detected -
Additional NNS to detect 1 high risk individual -
Females
Additional % of population screened -
Additional coverage of high risk population screened -
% of additional high risk individuals detected -
Additional NNS to detect 1 high risk individual -
* reference screening strategy is directly to the left of screening strategy assessed.
† first reference group (for ages ≥ 45).
NNS numbers needed to screen.Incremental costs
The cost of detecting one additional high-risk individual
increased exponentially as the targeted screening popu-
lation coverage increased incrementally (Table 5). As
younger and younger individuals were screened, the
additional cost for detecting one high-risk individualscular risk populations for various screening strategies
Targeted screening Universal
≥ age 45 ≥ age 40 ≥ age 35 screening
24.27 20.79 20.45 18.39
4.32 1.11 0.18 0.00
4.59 1.11 0.17 0.01
9.81 41.20 309.67 7168.90
26.96 22.20 21.99 19.12
5.62 1.53 0.25 0.00
6.08 1.55 0.25 0.01
6.12 23.61 176.52 5179.06
21.88 19.49 19.00 17.67
1.97 0.41 0.01 0.00
2.04 0.36 0.05 0.01
28.53 173.39 1525.92 5876.37
Table 5 Cost, incremental cost and impact of screening strategies
Targeted screening Universal
≥ age 50† ≥ age 45 ≥ age 40 ≥ age 35 screening
Overall
Estimated cost to detect 1 high risk individual, MYR (USD) 92.64 (29.73) 110.08 (35.33) 131.51 (42.20) 158.13 (50.75) 187.2 (60.08)
Incremental cost per additional high risk individual detected, MYR - 490.27 2060.12 15483.29 358444.85
(USD) - (157.34) (661.14) (4968.96) (115033.65)
NNS to prevent one CV event 62.24 76.14 96.64 123.95 146.73
NNS to prevent one CV event (sensitivity analyses) 168.47 206.07 261.57 335.48 397.15
Males
Estimated cost to detect 1 high risk individual, MYR (USD) 69.05 (22.16) 82.64 (26.52) 99.44 (31.91) 121.01 (38.84) 144.13 (46.25)
Incremental cost per additional high risk individual detected, MYR - 306.21 1180.58 8825.99 258952.77
(USD) - (98.27) (378.88) (2832.47) (83104.23)
NNS to prevent one CV event 45.33 57.27 72.96 94.33 112.36
NNS to prevent one CV event (sensitivity analyses) 120.13 151.77 193.36 249.97 297.77
Females
Estimated cost to detect 1 high risk individual, MYR (USD) 133.01 (42.69) 158.88 (50.99) 189.18 (60.71) 225.02 (72.21) 264.83 (84.99)
Incremental cost per additional high risk individual detected, MYR - 1426.50 8669.32 76295.96 293818.47
(USD) - (457.8) (2782.19) (24485.23) (94293.47)
NNS to prevent one CV event 85.72 105.59 129.78 165.01 194.20
NNS to prevent one CV event (sensitivity analyses) 240.97 394.25 364.83 463.95 545.95
CV cardiovascular, NNS numbers needed to screen.
MYR Malaysian Ringgit, USD US Dollar. 1.00 USD = 3.11600 MYR.
* for incremental costs, reference screening strategy is directly to the left of screening strategy assessed.
† first reference group (for ages ≥ 45).
Selvarajah et al. BMC Cardiovascular Disorders 2013, 13:10 Page 7 of 10
http://www.biomedcentral.com/1471-2261/13/10differed significantly among the sexes. For those
aged ≥45 years, the incremental cost for detecting an
additional high-risk individual among women was 4.7
times that of men. Once the eligibility age of screening
reduced to ≥ 35 years, the incremental cost among
women was 8.6 times that of men.
Discussion
Our study shows that a targeted cardiovascular risk
screening strategy would be better than the policy
recommendation of screening for all ages at a commu-
nity level (universal screening). Defining an age eligibility
criteria would be a more cost effective method of identi-
fying high-risk individuals. In addition, our study
highlights the need for different screening strategies for
men and women due to a significant difference in their
overall cardiovascular risk.
The findings of our study have important implications
for policy makers in the prevention and management of
cardiovascular disease. Firstly, high rates of cardiovascu-
lar risk factors in the country, do not necessarily trans-
late into high overall cardiovascular risk. A previous
study on cardiovascular risk factors showed a very high
prevalence of hypertension (38%), diabetes (11%), hyper-
cholesterolemia (24%), central obesity (37%) and it’s
clustering (33%) [2]. This was more pronounced inwomen. Our study showed that overall cardiovascular
risk was more severe in men than women, for all ages.
Therefore, having identical screening strategies for both
sexes may not be necessary or cost-effective.
Secondly, there are various factors which help deter-
mine the optimal screening strategy to be recommended;
the numbers needed to screen to detect one high-risk
individual, its cost and number of cardiovascular events
prevented. Our results show that universal screening
would cost twice as much as screening those aged ≥50
but detect high-risk individuals at half the rate. Aside
from that, universal screening would only detect an add-
itionally very small percentage of high-risk individuals.
Thirdly, comparing screening strategies by estimating
the incremental cost and effectiveness provides a clearer
picture of how much more is paid to identify an add-
itional high-risk individual. By limiting the age for
screening to just ≥35 years compared to the general
community, the incremental cost spent for detecting one
additional high-risk individual can be brought down
significantly. Aside from this, the discrepancies in cost
are substantial between the sexes. Choosing the optimal
screening strategy will depend on the amount policy
makers and financiers are willing to pay for each add-
itional high-risk individual detected. Finally, the impact
of these strategies clearly show that universal screening
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events prevented over ten years, when compared to
screening those aged 50 and above.
Ideally, the decision to recommend a cardiovascular
screening strategy should depend on two factors. First,
the ability of the screening strategy to detect the highest
proportion of high-risk individuals at an acceptable cost,
and second, the ability of healthcare facilities to manage
the treatment of these individuals from a financial and
human resource perspective. Policy makers and
programme planners will have to take these factors into
account when deciding the recommended screening
strategy for the country. This is especially important for
Malaysia where up to 64.5% of the population seek
health care from public facilities funded by the govern-
ment [1]. This study highlighted that the high incremen-
tal costs and very low impact for universal screening
may not be justifiable for implementation.
From a public health perspective, this study illustrates
that developing countries without available information
on, or the resources to obtain information on long term
risk of cardiovascular disease and outcomes, can use
existing cardiovascular risk scores and global risk-
reduction estimates to make informed decisions. While
these estimated may not be 100% accurate, they provide
a clear picture on the impact of various screening strat-
egies based on observed risk-factor prevalences in the
country.
There have been very few studies which have
examined the effectiveness and impact of screening
strategies for the prevention of cardiovascular diseases
using real population data. Chamnan et al. [8] assessed
the potential impact of various screening strategies in
the United Kingdom using data from a single county.
They too found that limiting screening to those older
than 50 years, or using routine general practice data
already available to pre-stratify high-risk individuals were
more (cost) effective than screening the general popula-
tion. For Scotland, Lawson et al. found that targeting
individuals with a family history of premature cardiovas-
cular disease was the most cost-effective measure [15].
However, their assessment of cost-effectiveness only
took into account the cost of screening and identifica-
tion of high-risk individuals. They did not account for
the impact of screening. Our study used data from a
nationwide population-based survey and took into
consideration the observed treatment uptake and adher-
ence rates. Our study also accounted for the impact of
treatment on high-risk individuals for the various
screening strategies.
Our study is not without limitations. The Framingham
Risk Score has not been validated in our multi-ethnic
population. Therefore, it’s accuracy in prognostication of
risk is unclear. However, it has been shown to accuratelyrisk stratify but overestimate cardiovascular risk in some
European, Australian and Middle Eastern populations
[16-18]. An earlier version of the FRS algorithm [19] had
been validated in a Chinese population. For the Chinese
population, it too accurately risk stratifies but
overestimates the coronary heart disease risk [20]. If the
FRS similarly overestimates cardiovascular risk in Asian
populations, the findings of this study are even more
important, because for similar risk scores, less cardiovas-
cular events occur in Asians. Thus, screening strategies
can be recommended for those with higher Framingham
risk scores (eg. 30% and above), or for older age groups
because they have higher proportions of high-risk
individuals. For women, a higher risk score cut-off than
men will be warranted. Aside from this, with lower
actual cardiovascular rates, the impact of these screening
strategies would be even more reduced for every
estimated cardiovascular risk. The numbers needed to
screen to prevent a single cardiovascular event would
increase substantially. This would be more so for
women, with lower age cut-off points, and would be
worst with universal screening.
Similarly, relative risk reductions for treatment of
cardiovascular risk factors have not been assessed in our
population. Nevertheless, research has confirmed that
risk reduction estimates have been found to be consist-
ent across populations around the world [21]. In this
study, the relative risk reductions were for cardiovascu-
lar disease outcomes except for smoking, which was
related to mortality.
In our study, the relative risk reduction for each inter-
vention was assumed to be independent of each other.
Synergistic effects of multiple drug and lifestyle
interventions may be present and most likely will have
different impacts for the various screening strategies.
However, this may also be true for side effects and
complications of treatment, thus the true impact of any
treatment strategy may not be so easily determined.
We did not account for cardiovascular screening
uptake in this study. In other populations, screening
uptake can be as low as 32% [22]. In Malaysia, there has
been one published paper which described cardiovascu-
lar screening uptake in a semi-rural community in 1993
[23]. The response rate to screening invitation was 56%.
However, it ranged up to 90% depending on the village
invited. This high variability in screening uptake suggests
that the modelled strategies in this study will have
differing impact and effectiveness, depending on the
screening acceptance rates of the respective communi-
ties as well as the cardiovascular risk distribution among
respondents. As we were not able to estimate the vari-
ability of cardiovascular risk distribution in participants
for various rates of screening uptake, we chose to
model a 100% uptake for universal screening, with a
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of the NHMS III. In the NHMS III, the response rate
was 94.6% [1]. This method represents the best case
scenario for the Malaysian context. In the study by Chin
et al., non-responders to the cardiovascular screening
invitation were of a similar age-and-gender distribution
as responders [23]. Aside from this, in a Japanese study
of non-participation to screening and mortality risks,
they showed that the lack of participation to screening
was not associated with an increased risk of cardiovascu-
lar mortality for men [24].
Conclusion
Policy recommendations for general cardiovascular
screening should be gender-specific with different age
group targets. This is to ensure optimal utilisation of
scarce resources for the identification of high-risk
individuals in the prevention of cardiovascular disease in
Malaysia.
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